Central and East European Oncology Group

CEEOG projects

OLIMPIA, D081CC00006 - A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Ne
INSIGHT - Imlepmentation of Presonalized Medicine in NSCLC: EGFR testing, histopatological an clinical features
CLOVIS CO-1686-006 - A prospective study to evaluate the concordance of tumor-associated mutations detected in matched tumor and blood samples in patients with NSCLC with known epidermal growth factor receptor mutational status
BIG 1-98 - A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors
APHINITY - A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer, BO25126
ACELUNG - Phase III trial evaluating the role of adjuvant celecoxib in completely resected, high-risk (pN1-2) non-small-cell lung cancer (NSCLC) patients.
PathIES - Intergroup Exemestane Study Pathology Sub-Study
LA-REMA - Retrospective analysis of molecular factors predictive for clinical efficacy of lapatinib in HER2-positive advanced breast cancer patients.
FLIKER - An open label phase II study evaluating the effectiveness of first line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients selected by positive FISH EGFR test


Medical University of Gdańsk
Department of Oncology and Radiotherapy
7 Dębinki Street, 80-211 Gdańsk, Poland
phone: +48 58 584 4560
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.